Comparison effect of Bucerelin, Daily Triptorelin 0.1 Mg and Triptorelin 0.1 MgThree times a week on the final results of assisted reproductive cycles .

Comparison effect of Bucerelin, Daily Triptorelin 0.1 Mg and Triptorelin 0.1 MgThree times a week on the final results of assisted reproductive cycles(ART)In infertility women referred to Tehran Vali Asr Infertility Clinic.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201308275181N10

Enrollment

138

Registered

2013-10-16

Start date

2013-02-03

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female infertility. Female infertility associated with anovulation

Interventions

Intervention 1: In group 1 , Daily cycle of 21 days, 0/5 mL BUcerelin ampoules and the third day of the next cycle will be treated with gonadotropin .After seeing at least two dominant follicle of si

Treatment - Drugs

In group 1 , Daily cycle of 21 days, 0/5 mL BUcerelin ampoules and the third day of the next cycle will be treated with gonadotropin .After seeing at least two dominant follicle of size 18 mm HCG Amp

In group 2, Daily cycle of 21 days, daily injections of 0.1 mg subcutaneous Tryptorelin and the third day of the next cycle will be treated with gonadotropin .After seeing at least two dominant foll

in the third group , Daily cycle of 21 days, every other day injections of 0.1 mg subcutaneous Tryptorelin and the third day of the next cycle will be treated with gonadotropin .After seeing at least

Eligibility

Sex/Gender

Female

Age

18 Years to 38 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria : indication of IVF ?age 18-38 years ?Exclusion criteria: FSH:>10? severe male infertility factor such as Azospermia? andomeriosis .

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Chemical pregnancy. Timepoint: two weeks after pregnancy. Method of measurement: blood test.;Clinical pregnancy. Timepoint: two weeks after pregnancy. Method of measurement: sonography.;Twin. Timepoint: two weeks after pregnancy. Method of measurement: sonography.;No, retrived oocyte. Timepoint: in the day of pick up oocyte. Method of measurement: sonography.;No,Embryos obtained. Timepoint: in the day ofEmbryo transfer. Method of measurement: sonography and specialist Diagnosis.	—

Measure

Time frame

Chemical pregnancy. Timepoint: two weeks after pregnancy. Method of measurement: blood test.;Clinical pregnancy. Timepoint: two weeks after pregnancy. Method of measurement: sonography.;Twin. Timepoint: two weeks after pregnancy. Method of measurement: sonography.;No, retrived oocyte. Timepoint: in the day of pick up oocyte. Method of measurement: sonography.;No,Embryos obtained. Timepoint: in the day ofEmbryo transfer. Method of measurement: sonography and specialist Diagnosis.

—

Secondary

Measure	Time frame
No of follicles. Timepoint: The sixth day of ovulation and Within two to three days. Method of measurement: Transvaginal sonography.;No of Gonadotropin Ampules used. Timepoint: after Embryo transfer. Method of measurement: Specialist administration.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahrokh Tehraninejad Ensieh

Vali-e-Asr reproductive HealthnResearch center

tehraninejad@yahoo.com+98 21 6693 9320

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026